Humacyte (HUMA) Competitors $1.54 -0.04 (-2.22%) As of 03:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HUMA vs. RCUS, LENZ, ZYME, VALN, SYRE, MLYS, STOK, NUVB, VERV, and PRAXShould you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Arcus Biosciences (RCUS), LENZ Therapeutics (LENZ), Zymeworks (ZYME), Valneva (VALN), Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), Stoke Therapeutics (STOK), Nuvation Bio (NUVB), Verve Therapeutics (VERV), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry. Humacyte vs. Its Competitors Arcus Biosciences LENZ Therapeutics Zymeworks Valneva Spyre Therapeutics Mineralys Therapeutics Stoke Therapeutics Nuvation Bio Verve Therapeutics Praxis Precision Medicines Arcus Biosciences (NYSE:RCUS) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations. Which has more volatility & risk, RCUS or HUMA? Arcus Biosciences has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500. Is RCUS or HUMA more profitable? Humacyte has a net margin of 0.00% compared to Arcus Biosciences' net margin of -109.56%. Humacyte's return on equity of 0.00% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Arcus Biosciences-109.56% -55.96% -25.73% Humacyte N/A N/A -78.26% Do analysts prefer RCUS or HUMA? Arcus Biosciences currently has a consensus price target of $21.14, suggesting a potential upside of 102.32%. Humacyte has a consensus price target of $9.75, suggesting a potential upside of 531.07%. Given Humacyte's stronger consensus rating and higher possible upside, analysts clearly believe Humacyte is more favorable than Arcus Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcus Biosciences 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Humacyte 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, RCUS or HUMA? Humacyte has lower revenue, but higher earnings than Arcus Biosciences. Humacyte is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcus Biosciences$262M4.25-$283M-$3.17-3.30Humacyte$1.57M155.85-$148.70M-$0.45-3.43 Do institutionals and insiders have more ownership in RCUS or HUMA? 92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 5.1% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to RCUS or HUMA? In the previous week, Arcus Biosciences and Arcus Biosciences both had 6 articles in the media. Arcus Biosciences' average media sentiment score of 1.47 beat Humacyte's score of 1.19 indicating that Arcus Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Humacyte 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryHumacyte beats Arcus Biosciences on 10 of the 16 factors compared between the two stocks. Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HUMA vs. The Competition Export to ExcelMetricHumacyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$243.10M$3.07B$5.76B$9.75BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-3.4120.9431.4526.36Price / Sales155.85352.55431.04155.09Price / CashN/A44.7137.7559.42Price / Book51.508.0110.536.57Net Income-$148.70M-$53.98M$3.28B$265.92M7 Day Performance-2.22%-1.24%0.37%0.06%1 Month Performance-34.81%5.19%5.15%1.99%1 Year Performance-74.88%8.80%50.24%20.91% Humacyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HUMAHumacyte2.546 of 5 stars$1.55-2.2%$9.75+531.1%-75.5%$243.10M$1.57M-3.41150Positive NewsAnalyst ForecastRCUSArcus Biosciences2.393 of 5 stars$10.45+0.6%$21.14+102.3%-38.5%$1.11B$258M-3.30500News CoverageLENZLENZ Therapeutics2.0238 of 5 stars$38.77+2.4%$49.60+27.9%+72.9%$1.11BN/A-20.41110High Trading VolumeZYMEZymeworks0.0765 of 5 stars$14.05-2.2%N/AN/A$1.06B$76.30M-14.48460VALNValneva2.0745 of 5 stars$12.14+5.3%$15.50+27.7%+16.6%$1.03B$183.52M-12.39700Gap UpHigh Trading VolumeSYRESpyre Therapeutics3.0779 of 5 stars$16.94-0.1%$53.40+215.2%-40.3%$1.02B$890K-4.9873News CoveragePositive NewsMLYSMineralys Therapeutics3.1255 of 5 stars$15.34+5.6%$32.25+110.2%+25.6%$1.02BN/A-4.3128News CoveragePositive NewsAnalyst ForecastSTOKStoke Therapeutics4.497 of 5 stars$18.51+1.6%$25.57+38.1%+44.0%$1.01B$36.56M21.78100Positive NewsNUVBNuvation Bio2.2225 of 5 stars$2.90+5.5%$7.33+152.9%-10.9%$992.58M$7.87M-4.6060VERVVerve Therapeutics2.7637 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110PRAXPraxis Precision Medicines1.7328 of 5 stars$46.63-1.0%$85.88+84.2%-9.9%$981.56M$8.55M-3.79110 Related Companies and Tools Related Companies RCUS Competitors LENZ Competitors ZYME Competitors VALN Competitors SYRE Competitors MLYS Competitors STOK Competitors NUVB Competitors VERV Competitors PRAX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HUMA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access